Ola Lindén
1 – 5 of 38
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Targeted Alpha Therapy, an Emerging Class of Cancer Agents : A Review
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
(
- Contribution to journal › Article
- 2015
-
Mark
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.
(
- Contribution to journal › Article
-
Mark
Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
2015) In European Journal of Haematology(
- Contribution to journal › Article
-
Mark
Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women - a Swedish Lymphoma Registry study.
(
- Contribution to journal › Article